Cogent Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	126.09	63.58	43.28	34.38	26.21	19.64
Research & Development	296.83	269.78	232.66	173.76	121.63	55.91
Operating Expenses	422.92	333.36	275.94	208.13	147.84	75.55
Operating Income	-422.92	-333.36	-275.94	-208.13	-147.84	-75.55
Interest Expense	-4.96	-3.06	-	-	-	-
Interest & Investment Income	27.6	14.69	18.09	13.08	3.99	0.47
Other Non Operating Income (Expenses)	-1.36	-0.02	1.99	2.64	3.61	2.81
EBT Excluding Unusual Items	-401.64	-321.76	-255.86	-192.41	-140.24	-72.27
Other Unusual Items	-7.18	-7.18	-	-	-	-
Pretax Income	-407.68	-328.94	-255.86	-192.41	-140.24	-72.27
Earnings From Continuing Operations	-	-328.94	-255.86	-192.41	-140.24	-72.27
Net Income	-407.68	-328.94	-255.86	-192.41	-140.24	-72.27
Net Income to Common	-407.68	-328.94	-255.86	-192.41	-140.24	-72.27
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	164	129	104	80	59	39
Shares Outstanding (Diluted)	164	129	104	80	59	39
Shares Change	37.67%	24.09%	30.48%	35.41%	51.89%	249.52%
EPS (Basic)	-2.48	-2.55	-2.46	-2.42	-2.38	-1.87
EPS (Diluted)	-2.48	-2.55	-2.46	-2.42	-2.38	-1.87
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-325.78	-266	-208.36	-156.42	-125.5	-60.48
Free Cash Flow Per Share	-1.98	-2.06	-2.00	-1.96	-2.13	-1.56
EBITDA	-420.36	-330.8	-273.49	-205.86	-147	-75.4
D&A For EBITDA	2.57	2.56	2.45	2.27	0.84	0.15
EBIT	-422.92	-333.36	-275.94	-208.13	-147.84	-75.55

SEC Filings: 10-K · 10-Q